

U.S.S.N. 09/148,012

Filed: September 4, 1998

AMENDMENT AND RESPONSE TO OFFICE ACTION

5. (amended) The method of claim 2 wherein the compound increases SR-BI expression in [the] a tissue of the mammal.

6. (amended) The method of claim 3 wherein the compound decreases SR-BI binding to lipoprotein or transfer of cholesteryl ester in [the] a tissue of the mammal.

7. (amended) The method of claim 3 wherein the compound increases SR-BI binding to lipoprotein or transfer of cholesteryl ester in [the] a tissue of the mammal.

9. (amended) The method of claim 1 wherein the mammal has a disorder characterized by an overproduction of steroids.

10. (amended) The method of claim 1 wherein the mammal has a disorder characterized by an underproduction of steroids.

Please cancel claim 11.

Please cancel claims 13 and 14.

Remarks**Objection to Claims**

Claims 9 and 10 have been amended as recommended by the examiner.

Restriction Requirement

The examiner has apparently restricted claims into two groups, group I, claims 1-18, and 20-22, and group II, claim 19, and withdrawn claim 19 from consideration. Confirmation of this restriction requirement and action, which would preclude requiring a terminal disclaimer if a divisional application drawn to claim 19 is filed, would be appreciated.

Rejection Under 35 U.S.C. § 112, first paragraph